| Mr Subroto Kundu, MD | |
|
3555 Keith St Nw, Suite 211, Cleveland, TN 37312-4375 | |
| (423) 790-1529 | |
| (423) 790-1589 |
| Full Name | Mr Subroto Kundu |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 43 Years |
| Location | 3555 Keith St Nw, Cleveland, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063426302 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Regional One Health | Memphis, TN | Hospital |
| Entity Name | East Tn Neurology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538424072 PECOS PAC ID: 2365691474 Enrollment ID: O20121005000081 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
A landmark paper identifying genetic signatures that predict which patients will respond to a life-saving drug for treating congestive heart failure has been published by a research team co-led by Stephen B. Liggett, MD, of the University of South Florida.
Today's major health policy headlines include reports about the latest developments in Virginia's court challenge against the health law, a U.S. government lawsuit targeting Michigan Blue Cross Blue Shield for anti-trust activities and a study about the Department of Health and Human Services' Hospital Compare.
› Verified 7 days ago
| Entity Name | Ut Regional One Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093130585 PECOS PAC ID: 5698993418 Enrollment ID: O20140820000662 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
A landmark paper identifying genetic signatures that predict which patients will respond to a life-saving drug for treating congestive heart failure has been published by a research team co-led by Stephen B. Liggett, MD, of the University of South Florida.
Today's major health policy headlines include reports about the latest developments in Virginia's court challenge against the health law, a U.S. government lawsuit targeting Michigan Blue Cross Blue Shield for anti-trust activities and a study about the Department of Health and Human Services' Hospital Compare.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Subroto Kundu, MD 3555 Keith St Nw, Suite 211, Cleveland, TN 37312-4375 Ph: (423) 790-1529 | Mr Subroto Kundu, MD 3555 Keith St Nw, Suite 211, Cleveland, TN 37312-4375 Ph: (423) 790-1529 |
News Archive
Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
A landmark paper identifying genetic signatures that predict which patients will respond to a life-saving drug for treating congestive heart failure has been published by a research team co-led by Stephen B. Liggett, MD, of the University of South Florida.
Today's major health policy headlines include reports about the latest developments in Virginia's court challenge against the health law, a U.S. government lawsuit targeting Michigan Blue Cross Blue Shield for anti-trust activities and a study about the Department of Health and Human Services' Hospital Compare.
› Verified 7 days ago
Dr. Stephan Max Becker, M.D. Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 2033 N Ocoee St, Cleveland, TN 37311 Phone: 423-458-1020 Fax: 833-637-0070 | |
Mrs. Gulshan A Sultan, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1600 Clingan Ridge Dr, Cleveland, TN 37312 Phone: 423-472-3141 Fax: 423-478-5160 | |
Troy Gilson, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 940 S Ocoee St, Cleveland, TN 37311 Phone: 423-479-5454 | |
Dr. Niansen Liu, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3555 Keith St Nw, Ste 102, Cleveland, TN 37312 Phone: 423-728-2282 Fax: 423-728-2234 | |
Dr. Taylor Clay Bear, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2253 Chambliss Ave Nw Ste 400, Cleveland, TN 37311 Phone: 423-476-5002 Fax: 423-476-5969 | |
Dr. James F Hart, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2700 Westside Dr Nw Ste 204, Cleveland, TN 37312 Phone: 423-728-1667 Fax: 423-472-0266 |